Unraveling severe sepsis - Why did OPTIMIST fail and what's next?

被引：27
作者：
Angus, DC
Crowther, MA
机构：
[1] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Lab, Pittsburgh, PA 15261 USA
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 02期
关键词：
D O I：
10.1001/jama.290.2.256
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256 / 258
页数：3
相关论文
共 35 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review [J].
Vincent, JL ;
Abraham, E ;
Esmon, C ;
Hack, CE .
CRITICAL CARE MEDICINE, 2000, 28 (09) :S33-S33
[3]   The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome [J].
Aird, WC .
BLOOD, 2003, 101 (10) :3765-3777
[4]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[5]   Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis [J].
Angus, DC ;
Linde-Zwirble, WT ;
Clermont, G ;
Ball, DE ;
Basson, BR ;
Ely, EW ;
Laterre, PF ;
Vincent, JL ;
Bernard, G ;
van Hout, B .
CRITICAL CARE MEDICINE, 2003, 31 (01) :1-11
[6]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[7]   Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study [J].
Baudo, F ;
Caimi, TM ;
de Cataldo, F ;
Ravizza, A ;
Arlati, S ;
Casella, G ;
Carugo, D ;
Palareti, G ;
Legnani, C ;
Ridolfi, L ;
Rossi, R ;
D'Angelo, A ;
Crippa, L ;
Giudici, D ;
Gallioli, G ;
Wolfler, A ;
Calori, G .
INTENSIVE CARE MEDICINE, 1998, 24 (04) :336-342
[8]   Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis [J].
Bernard, GR ;
Ely, EW ;
Wright, TJ ;
Fraiz, J ;
Stasek, JE ;
Russell, JA ;
Mayers, I ;
Rosenfeld, BA ;
Morris, PE ;
Yan, SB ;
Helterbrand, JD .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2051-2059
[9]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[10]   Why sepsis trials fail [J].
Bone, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07) :565-566
1234